NEUROCRINE BIOSCIENCES INC — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Neurocrine Biosciences amended its 2025 Equity Incentive Plan on March 17, 2026 (approved by stockholders May 27, 2026). The plan authorizes 11.8M total shares: 7.8M approved at 2025 Annual Meeting + 4.0M approved at 2026 Annual Meeting, plus returning shares from prior plans. The plan permits grants of options, SARs, RSUs, restricted stock, and performance awards to employees, directors, and consultants, with standard administrative provisions and no material change from typical equity plan structure.
Why this rating
Routine equity plan amendment. Share reserve (~11.8M) is ~0.3% of $9.5B market cap—immaterial. Standard boilerplate governance document.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.